Revance to Participate in Upcoming Investor Conferences
Revance Therapeutics, Inc, announced the commercial launch of Daxxify (DaxibotulinumtoxinA-lanm) for injection for the treatment of cervical dystonia, providing patients and physicians with a compelling new treatment option for a painful and disabling chronic condition. The launch marks Revance Therapeutics’ entry into the large and growing US therapeutics neurotoxin market.
Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
Revance Reports Fourth Quarter and Full Year 2023 Financial Results
Revance to Participate in Upcoming Investor Conferences
Revance to Release Fourth Quarter and Full Year 2023 Financial Results